Female-specific expression of the Xenopus laevis vitellogenin gene was reconstituted in vitro by addition of recombinant vaccinia-virus-produced estrogen receptor to nuclear extracts from male livers, in which this gene is silent. Transcription enhancement was at least 30 times and was selectively restricted to vitellogenin templates containing the estrogen-responsive unit. Thus, in male hepatocytes, estrogen receptor is the limiting regulatory factor that in the female liver controls efficient and accurate sex-specific expression of the vitellogenin gene. Furthermore, the Xenopus liver factor B, which is essential in addition to the estrogen receptor for the activation of this gene, was successfully replaced in the Xenopus extract by purified human nuclear factor I, identifying factor B ofXenopus as a functional homolog of this well-characterized human transcription factor.
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In oviparous vertebrates, vitellogenin genes, which encode the precursor of yolk proteins, are transcribed under estrogen control in the liver of adult females. In contrast, males normally never produce vitellogenin, although hormone treatment of these animals can lead to a de novo activation of the vitellogenin genes in preexisting differentiated and nonproliferating hepatocytes (1, 2) . Earlier studies also demonstrated that in adult male liver, estrogen treatment increases the estrogen receptor (ER) level from 100-200 molecules per uninduced hepatocyte to about 1500 molecules per fully stimulated cell. Progressive activation of vitellogenin gene transcription follows the increase of ER with a 4-to 6-hr lag (3, 4) . However, it is not known whether the absence of vitellogenin gene expression in male livers results solely from the low liver estrogen concentration (0.18 nM) and the accompanying very low level of receptor (see above) or whether other essential components of the vitellogenin gene stimulation machinery must first be produced de novo in hepatocytes as a primary effect of hormone preceding activation of the gene.
To address this point, which is crucial for the understanding of the sex-specific expression of the vitellogenin gene, we used tissue-specific nuclear extracts. Such extracts prepared from estrogen-induced Xenopus laevis female liver are capable of directing steroid hormone-dependent in vitro transcription (5) . Analysis of the Xenopus vitellogenin gene B1 promoter region revealed that in addition to the estrogenresponsive element, at least two sequence elements play crucial roles in the regulation of this promoter in female liver (6) . One of them, a negative regulatory element (NRE), is responsible for the lack of promoter activity in the absence of the hormone and interacts with a liver-specific transcription factor. The second is similar to the nuclear factor I (NF-I) consensus recognition sequence and is required in association with the estrogen-responsive element (ERE) to mediate hormonal induction. It is recognized by the Xenopus liver factor B.
Using a similar in vitro transcription system but derived from male liver, we demonstrate that in male hepatocytes ER is the limiting regulatory factor which in the female liver regulates the expression of the vitellogenin gene. Furthermore, the Xenopus liver factor B, which is essential in addition to the ER for the activation of this gene, was identified as the functional homolog of NF-I.
MATERIALS AND METHODS
Templates for in Vitro Transcription. All deletion mutants used are diagramed in Fig. 1 Upper and all contain the vitellogenin B1 promoter up to position +8. The 5' deletion mutants have been described previously (6) . The 3' deletion mutant fragments of the gene B1 promoter region were cloned in front of the minimal (-41/+8) B1 promoter containing the natural transcription initiation site and the TATA box of the vitellogenin B1 gene (7).
Preparation of Nuclear Extracts from Xenopus Livers and
Regulatory Factor Depletion Procedure. Nuclear extracts for transcription were prepared from X. laevis livers by the method of Gorski et al. (8) with the modifications described (9) . The nuclear proteins were stored in liquid nitrogen in the nuclear extract dialysis buffer containing 25 mM Hepes (pH 7.9), 60 mM KCI, 1 mM dithiothreitol, and 10% (vol/vol) glycerol. Protein concentration in the extracts was determined by the Bradford procedure using bovine serum albumin as the standard.
Depletion of the liver factor B from the X. laevis nuclear extracts was carried out with an affinity matrix containing the binding site for the NF-I activity as described (10) . The depleted extracts were not stored but immediately used for in vitro transcription. To get the affinity matrix, CNBractivated Sepharose CL-2B (Pharmacia) was prepared according to the manufacturer's directions. Coupling with the double-stranded NF-I Ad2 oligonucleotide (binding site underlined) 5'-TATACCTTATTTT-GATTGAAGCCAATAT-GATAATGAG-3' in multiple copies (10- (ERU) . The filled rectangle and filled triangle correspond to the previously mapped binding site for the hepatic NF-I-like factor B and for the repressor C, respectively (6) . (12), except that buffers contained benzamidine, leupeptin, pepstatin A, chymostatin, and antipain at a final concentration of 1 jig/ml.
Partial purification of the xER protein was performed by loading 10 mg of the xER-containing whole cell extract in buffer B [20 mM Tris-HCI, pH 7.5/20% (vol/vol) glycerol/2 mM dithiothreitol/5 /LM ZnCl2/0.1 M KCI] onto a 1-ml heparin-Sepharose CL-6B column (Pharmacia) equilibrated with the same buffer. The bound proteins were eluted stepwise with buffer B but containing increasing concentration of KCI (0.1-1 M). The fractions (200 ul) containing the xER activity were identified by the mobility shift assay using a 3-,u1 aliquot in a 20-pul reaction volume. Pools of fractions corresponding to the different elution steps were dialyzed separately and progressively against buffer B (0.1 M KCJ) and assayed (3-IA aliquot of pooled fraction) for xER binding activity as above.
In Vitro Transcription and Transcript Analysis. In vitro transcription was performed as described (6) . The amount of specific Vit-CAT mutant constructs was as indicated in the figure legends and that ofthe control template pSV2CAT (250 ng) was maintained constant in all reaction mixtures. The products of transcription were analyzed by primer extension and resolved by 6% polyacrylamide/7.5 M urea gel electrophoresis.
Gel Retardation Assay. Mobility shift assays were performed as described (12) in the presence of 50 nM hormone with a 3'-labeled double-stranded oligonucleotide containing the vitellogenin gene A2 ERE (minimal element is underlined) 5'-GATCCGGGGTCACAGTGACCTA-3' (13) 
and suggest that induced male liver nuclear extracts are functionally equivalent to female extracts (6) .
Analysis of the 3' deletion mutants further demonstrated that an additional element, called B (filled rectangle in Fig. 1 Upper), is required in association with the upstream ERU to mediate hormonal induction ( Fig. 1 Lower Right). Consistently, the ERU is unable to confer inducibility in the absence of element B unless the former is placed immediately upstream of the TATA box (compare mutants -135, -160, and -250 to mutant -287, Fig. 1 Lower Right). Although we consider it as unlikely, we cannot definitively exclude the possibility of the presence between positions -250 and -287 of an element inhibiting hormonal induction whose effect can be overcome only by element B.
Addition of ER to a Male Nuclear Extract Is Sufficient for Female-Specific Expression of the Vitellogenin Promoter. On the basis of the crucial finding presented above, we assumed that complementation of nuclear extracts prepared from noilinduced male liver could be used to identify the factor(s) involved in sex-specific expression of the vitellogenin promoter, which is silent in such extracts even in the presence of hormone. Because unstimulated and estrogen-treated hepatocytes contain the same set of basal transcription factors (6), we tested the hypothesis that the receptor is the limiting factor in the noninduced male extract. To this end, xER (16) was produced in HeLa cells via a recombinant vaccinia virus expressing the full-length receptor. The specific binding of the xER to the ERE was tested by gel retardation. Using the xER-containing extract, we observed the formation of a complex with a consensus ERE probe whose intensity increased with the amount of protein assayed ( Fig. 2A, lanes  8-13) . The presence of xER in this complex was confirmed by coincubation of the complex with the monoclonal antibody H222 raised against the hormone-binding domain of the human ER (17) (Fig. 2A, lane 14) . In addition, the binding was shown to be sequence specific, since the xER-probe association was prevented by excesses of the homologous oligonucleotide (Fig. 2B, lanes 2-4) but not by a 50-fold molar excess of an unrelated oligonucleotide (Fig. 2B, lane 5) . These results suggest that the xER produced from the recombinant virus binds specifically to its cognate binding site in the vitellogenin promoter. In contrast, when the control HeLa extract lacking xER (WR) was used no specific retarded band was observed ( Fig. 2A, lanes 1-5) . These two crude HeLa extracts containing or lacking receptor were used to complement uninduced male liver extracts (Fig. 3) . The -596 ERU-containing template was strongly activated after complementation of the liver nuclear extract with the whole-cell extract containing the receptor (Fig. 3A, lane 4) but not after complementation with the control extract from cells infected with the virus lacking receptor sequences (Fig.  3A, lane 3) . As expected, no transcription of the -301 template lacking the ERU was observed in either of these two complemented extracts, indicating that the activation seen with the -596 template is dependent on the receptor and the ERU.
To enrich the preparation in receptor, an extract from HeLa cells infected with the recombinant virus was fractionated on heparin-Sepharose (Fig. 4) . The different fractions were tested for ERE binding and for transcriptional complementation of the male liver extract. Only the column fraction containing the enriched receptor as identified by bandshift complemented the male extract, resulting in selective activation of the -596 template but not ofthe -301 template (Fig.   3B ).
Since the xER preparation contained no Xenopus liverspecific regulatory factors except the ER, our complementation experiments indicate that the uninduced male liver extract, in which the vitellogenin promoter is silenced via the NRE contains all the specific factors involved in the derepression and induction of the vitellogenin promoter except a sufficient amount of ER. Furthermore, complementation of the nontreated male liver extract with the crude or the enriched receptor preparations resulted in a promoter activity which was comparable to that observed with a female liver extract. Altogether, these observations indicate that the relevant difference between the sexes resides in the control of ER gene expression.
Functional Substitution of the Xenopus Liver Factor B by Human NF-I. As mentioned above, element B of the vitellogenin promoter (Fig. 1) binds a factor required to mediate estrogen responsiveness when the ERU is at a distance from the TATA box. This element, highly similar to a NF-I-binding site, is indeed able to bind purified human NF-I. Reciprocally, factor B recognizes the NF-I-binding site (6) . To further understand the involvement of specific regulatory factors in the vitellogenin promoter activation mechanism we asked whether the Xenopus liver factor B could be replaced with the well-characterized human NF-I (18). First, a female liver extract and an induced male liver extract were depleted of factor B by incubation with an affinity matrix containing the NF-I-binding site. These extracts were then complemented with human NF-I purified as described (18) . Remarkably, this factor is able to functionally complement the Proc. Natl. Acad. Sci. USA 87 (1990) A and B, respectively) indicates that, taking into account the amount of protein used for the complementation, the ER is enriched S times. This is in agreement with its enrichment in ERE-binding activity (see Fig. 4 ) and indicates that there is no loss of transactivation activity, compared to EREbinding activity, during chromatography. Thus, the heparin column represents a valuable first step towards the biochemical characterization and purification of the xER. depleted female and induced male extracts in mediating the hormonal stimulation with the same efficiency as the endogenous Xenopus factor B (Fig. 5) . Addition of the human factor to extracts that have not been depleted does not increase their hormone responsiveness, indicating that the endogenous factor B is not limiting in the transcription assay. To test if a complementation requiring more than one exogenously added factor is possible, we analyzed the effect of adding back to a factor-B-depleted, hormone-untreated male liver extract NF-I, xER, or both factors together. Consistent with the results above, neither protein added alone was sufficient for inducing transcriptional activation. In contrast, when a combination of the two factors was provided, the vitellogenin promoter was strongly activated. Together, these experiments show that the Xenopus liver factor B is homologous to human NF-I in both its DNA-binding properties (6) and its capacity to functionally cooperate with the ER in the sex-and tissuespecific promoter activation process. (19) . (9); lanes 2 and 6, addition of 2 footprint units (18) ofpurified human NF-I to a reaction mixture otherwise identical to 1 and 5; lanes 3 and 7, transcription with nuclear extract depleted of factor B by preincubation with an affinity matrix carrying an oligonucleotide corresponding to the binding site for NF-I, subsequently removed by centrifugation; lanes 4 and 8, complementation of the B-factor-depleted nuclear extract used in lanes 3 and 7 with 2 footprint units of purified human NF-I. Receptor and NF-I complementation: reaction mixtures for lanes 9 and 10 were as in Fig. 3 , but with complementation (lane 10) by both the xER preparation and the NF-I protein. Lane 11, B factor-depleted noninduced male liver nuclear extracts complemented with the xER preparation solely; lane 12, as in 11, but with addition of purified NF-I. served. Application of the substitution and complementation strategy will prove valuable in further defining the minimal combination of different factors necessary for the faithful hormone-and tissue-specific expression of the vitellogenin gene in vitro.
